Biosion key facts
as of Oct 2026- Developer of biomedical drugs intended for the treatment of immune and oncologic diseases.
- Biosion is valued at approximately $182.3M as of Oct 2026 (last reported valuation).
- It has raised $132.7M; the latest was Secondary Transaction - Private in Aug 2025.
- Notable investors include Addor Capital, Suzhou Guofa Venture Capital, Lapam Capital, GF Xinde Investment Management, Xiamen C&D Corporation — 17 tracked in total.
- Status: Privately Held (backing).
Biosion's last reported valuation, Dec 2020. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch Biosion: the Monday email on marks, rounds and moves
Biosion funding rounds
No funding rounds for Biosion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Biosion
17+Membership and data by Private Market View
Biosion valuation
Biosion's last reported valuation was $182 million in Dec 2020. No priced round, secondary trade or fund mark has surfaced since.
Biosion investors
17 investors are on record for Biosion, including Addor Capital, Suzhou Guofa Venture Capital, Lapam Capital and GF Xinde Investment Management.
About Biosion
Developer of biomedical drugs intended for the treatment of immune and oncologic diseases. The company's antibody-based therapies discovery platforms accelerate the discovery and development of biomedical drugs through mono and bi-specific protein therapeutics, enabling greater treatment potential for patients with related diseases.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2017
- Employees
- 90
- Website
- biosion.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.